Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer Biomarker
MT newswire2026/10/08 13:5709:57 AM EDT, 10/08/2026 (MT Newswires) -- Sophia Genetics (SOPH) and Myriad Genetics (MYGN) are collaborating to advance a new genomic instability score for prostate cancer, the companies said Thursday. The score will be generated using Myriad's MyChoice CDx test, which is currently used as a companion diagnostic in ovarian cancer, according to a joint statement. Under the collaboration, Sophia Genetics is developing a solid tumor application of its Extended Homologous Recombination Solution as a decentralized companion diagnostic using Myriad's score. Sophia Genetics shares were down more than 2% in recent trading Thursday, while Myriad Genetics fell over 3%. Price: 6.97, Change: -0.18, Percent Change: -2.52
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF
Crypto prices
More
